PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Futibatinib (Primary)
- Indications Cholangiocarcinoma; Glioblastoma; Glioma; Solid tumours; Urogenital cancer
- Focus First in man; Therapeutic Use
- Acronyms FOENIX-101
- Sponsors Taiho Oncology
- 06 Oct 2019 Planned number of patients changed from 371 to 385.
- 28 Jun 2019 Planned End Date changed from 1 Sep 2019 to 1 Jun 2020.
- 28 Jun 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History